Personalized Peptide Manufacture, a CMO approach
Cary Potochnik
NAPP™ Team Lead, Polypeptide Group
Exploration of personalized therapies presents new challenges in their manufacture. The processes must minimize turnaround times and be ready to execute on short notice while remaining robust enough to handle an novel product with each run. These problems are compounded by the regulatory expectations in manufacture of Drug Substance. Utilization of CMO’s to collaborate on these problems diversifies risk and allows increased flexibility around program scheduling.
Cary Potochnik previously led small scale GMP peptide manufacturing as the NAPP™ Team Lead at PolyPeptide Group, Torrance. During his tenure he was responsible for build out of a dedicated GMP suite, process implementation and optimization, and day to day operations. Cary obtained his degree in Chemistry from McGill University. Prior to joining the NAPP™ team, Cary worked in large scale API manufacture.